Retrospective analysis to describe associations between tumor necrosis factor alpha inhibitors and COPD-related hospitalizations
Open Access
- 1 July 2017
- journal article
- research article
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 12, 2085-2094
Abstract
Background: Limited information exists on the impact of tumor necrosis factor inhibition on COPD exacerbations. This retrospective study characterized this impact among COPD patients with underlying autoimmune conditions, exposed to tumor necrosis factor inhibitors (TNFi) and/or non-biologic disease-modifying antirheumatic drugs (DMARDs). Patients and methods: Adult COPD patients with ≥1 diagnosis for rheumatoid arthritis (RA), psoriasis (PsO), psoriatic arthritis (PsA), or ankylosing spondylitis (AS) before or within 6 months following the index COPD diagnosis were identified from the Truven Health MarketScan® databases. Patients were required to have a second claim for RA, PsO, PsA, AS, or DMARD use (biologic or non-biologic) prior to or up to 6 months following the index date. Incidence of COPD-related hospitalizations and emergency room (ER) visits was evaluated in relation to treatment with TNFi and/or DMARDs and other potential risk factors. Results: The study cohort included 40,687 patients (untreated, 37.7%; non-biologic DMARD, 35.4%; TNFi + non-biologic DMARD, 18%; TNFi, 8.8%). The proportion of patients with a COPD-related hospitalization and the incidence of COPD-related hospitalization (per 100 person-years) were lowest in the TNFi cohort (8.6%; 3.54, 95% confidence interval [CI]: 3.16–3.95) and the TNFi + non-biologic DMARD cohort (8.4%; 2.85, 95% CI: 2.63–3.08). In multivariate models, treatment with TNFi + non-biologic DMARD reduced the risk of COPD-related hospitalization or ER visits by 32% relative to non-biologic DMARDs (hazard ratio: 0.68; 95% CI: 0.61–0.75). Conclusion: In real-world settings, TNFi monotherapy confers similar risk for COPD-related hospitalization or ER visits as a non-biologic DMARD. Decreased risk was found among those treated with both TNFi and a non-biologic DMARD.Keywords
This publication has 16 references indexed in Scilit:
- Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritisAnnals of the Rheumatic Diseases, 2013
- COPD Surveillance—United States, 1999-2011Chest, 2013
- TNFα antagonists for acute exacerbations of COPD: a randomised double-blind controlled trialThorax, 2012
- Diagnosis and Management of Stable Chronic Obstructive Pulmonary Disease: A Clinical Practice Guideline Update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory SocietyAnnals of Internal Medicine, 2011
- Effect of Infliximab on Local and Systemic Inflammation in Chronic Obstructive Pulmonary Disease: A Pilot StudyRespiration, 2008
- TNF-α antagonists and the prevention of hospitalisation for chronic obstructive pulmonary diseasePulmonary Pharmacology & Therapeutics, 2008
- The Safety and Efficacy of Infliximab in Moderate to Severe Chronic Obstructive Pulmonary DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2007
- First Study of Infliximab Treatment in Patients with Chronic Obstructive Pulmonary DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2005
- Differences in Interleukin-8 and Tumor Necrosis Factor-Alpha in Induced Sputum From Patients With Chronic Obstructive Pulmonary Disease or AsthmaAmerican Journal of Respiratory and Critical Care Medicine, 1996
- Tumor Necrosis Factor-Alpha Increases Airway Responsiveness and Sputum Neutrophilia in Normal Human SubjectsAmerican Journal of Respiratory and Critical Care Medicine, 1995